01.04.2021 Vivoryon Therapeutics N.V.  NL00150002Q7

DGAP-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15th, 2021


 

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15th, 2021

01.04.2021 / 07:00
The issuer is solely responsible for the content of this announcement.


Vivoryon Therapeutics to Host Virtual Event on Current Clinical Landscape in Alzheimer's Disease Treatment Options with Leaders and Experts on April 15th, 2021

 

HALLE (SAALE) / MUNICH, GERMANY, 1 April 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) announced today that it will host a virtual event covering next steps in Alzheimer's Disease (AD) treatment options with leaders and experts in the field on Thursday, April 15th, 2021 from 5:00 - 7:00 pm CEST / 11:00 am - 1:00 pm EDT / 8:00 - 10:00 am PDT.


Despite repeated clinical trial failures in the AD space, a determined group of pharma and biotech companies has not given up on seeking for therapies that address the high unmet medical need in this indication. Vivoryon's interactive session will cover discussions surrounding current hurdles and exciting, novel approaches to the challenging AD space, including the company's clinical phase 2 compound, varoglutamstat, a small molecule inhibitor of glutaminyl cyclase (QC) capable of targeting all three hallmarks of AD: amyloid-beta, tau, and neuroinflammation.


Addressing the Alzheimer's Disease Puzzle in the Clinic: An Expert Overview
Participating AD experts include:

Professor Philip Scheltens, MD, PhD, Director at the Alzheimer Center Amsterdam and Managing Partner of the LSP Dementia Fund, will provide a general overview of the AD space and which approaches show promise in this complex indication.
 

Howard Feldman, MD, Professor, Department of Neurosciences and Director of the Alzheimer's Disease Cooperative Study at the University of California San Diego School of Medicine, will give a presentation of VIVA-MIND, a Phase 2a US National Institutes on Aging-funded trial of varoglutamstat planned to start later this year.
 

Frank Weber, MD, Chief Medical Officer at Vivoryon, will discuss VIVIAD, Vivoryon's European Alzheimer's Disease Phase 2b study with varoglutamstat.
 

The speakers will be available for a Q&A session at the conclusion of the event.
 

The event will be accessible via a live webcast through this link. A replay of the event will be available on Vivoryon's website following the presentation.

 

###


For more information, please contact:
Vivoryon Therapeutics N.V.
Dr. Ulrich Dauer, CEO
Email: [email protected]

Trophic Communications
Gretchen Schweitzer / Valeria Fisher
Tel: +49 172 861 8540 or +49 175 8041816
Email: [email protected]


About Vivoryon Therapeutics N.V.
With 20+ years of unmatched understanding in identifying post-translational modifying enzymes that play critical roles in disease initiation and progression, Vivoryon's scientific expertise has facilitated the creation of a discovery and development engine for small molecule therapeutics. This platform has demonstrated success by developing a novel therapeutic in type 2 diabetes. In its current programs Vivoryon is advancing its lead product, varoglutamstat (PQ912), in Alzheimer's disease and its entire portfolio of QPCT and QPCTL inhibitors in oncology and other indications. In addition, the company pursues a development program for Meprin protease inhibitors with potential therapeutic use in fibrotic diseases, cancer and acute kidney injury. www.vivoryon.com

Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



01.04.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Vivoryon Therapeutics N.V.
Weinbergweg 22
06120 Halle/Saale
Germany
Phone: +49 (0)345 555 9900
Fax: +49 (0)345 555 9901
E-mail: [email protected]
Internet: www.vivoryon.com
ISIN: NL00150002Q7
WKN: A2QJV6
Listed: Regulated Unofficial Market in Berlin, Frankfurt, Munich, Stuttgart; Amsterdam
EQS News ID: 1180316

 
End of News DGAP News Service

1180316  01.04.2021 

fncls.ssp?fn=show_t_gif&application_id=1180316&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2015 2016 2017 2018 2019 2020 2021e
Umsatzerlöse1 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBITDA1,2 -13,39 -13,67 -9,86 -7,68 -7,63 -15,87 0,00
EBITDA-Marge3 0,00 0,00 0,00 0,00 0,00 0,00 0,00
EBIT1,4 -13,39 -13,77 -9,96 -7,70 -7,72 -16,01 0,00
EBIT-Marge5 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Jahresüberschuss1 -13,51 -13,89 -8,01 -7,74 -7,82 -16,51 0,00
Netto-Marge6 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Cashflow1,7 -12,15 -13,26 -12,12 -6,99 -11,61 -14,01 0,00
Ergebnis je Aktie8 -1,97 -1,82 -0,98 -0,94 -0,62 -0,83 -0,51
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2020 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Vivoryon Therapeutics
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A2QJV6 17,820 355,96
KGV 2022e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 0,00 0,00 -16,39
KBV KCV KUV EV/EBITDA
16,85 - 0,00 -20,90
Dividende '20 in € Dividende '21e in € Div.-Rendite '21e
in %
Hauptversammlung
0,00 0,00 0,00 28.06.2021
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
25.06.2021 21.09.2021 04.11.2021 30.04.2021
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-4,72% 3,83% 95,18% 163,22%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Vivoryon Therapeutics N.V.  ISIN: NL00150002Q7 können Sie bei DGAP abrufen

Biotechnologie , A2QJV6 , 05Y , XETR:PB9